Author Archives: katie carrera

OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services Including the 4Kscore® Test

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced that it has entered into agreements with Stratose, Three Rivers Provider Network and Fortified Provider Network for testing services from OPKO Lab, including the 4Kscore®Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive cancer. The cumulative contracts, with some of the largest healthcare PPO network […]

OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (OPK) and Bio-Reference Laboratories, Inc. (BRLI), today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) has been granted, effective July 1, 2015, for OPKO’s planned acquisition of Bio-Reference. This Smart News Release features multimedia. View the full release here: Expiration of the waiting period […]

OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) today announced the decision of the National Comprehensive Cancer Network (NCCN) to include 4Kscore® as a recommended test in the 2015 NCCN Guidelines for Prostate Cancer Early Detection. The panel concluded that the 4Kscore, as a blood test with greater specificity over the PSA test, is indicated for use prior to a first […]

OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger

MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call and webcast at 8:30 a.m. ET on Thursday, June 11, 2015, to discuss the previously announced entry into a merger agreement for OPKO to acquire Bio-Reference Laboratories and to discuss Bio-Reference Laboratories’ second quarter financial results. This joint call will be in lieu of the separate earnings […]